Keith Berelowitz, Director of Operations at Richmond Pharmacology, outlines in an article for Health Investor how innovations in the design and delivery of clinical trials are generating time and cost savings for industry. 

Brexit and COVID-19 have shed a light on the importance of swift and cost-effective clinical trial development within the UK. Adaptive trials are a game changing process within clinical research and use of these protocols by CROs such as Richmond Pharmacology has demonstrated considerable value for sponsors and investors. These benefits include faster trial assessment and conclusion and the efficient use of resource compared to more rigid traditional clinical trial processes. Ultimately these new processes also help to speed the path of promising new medicines to patients as well.

Despite the advancements brought to the clinical environment by adaptive trials, these processes have not become standard practice yet among all CROs. As clinical research becomes ever more important within UK’s economic, medical, and R&D environments, it is important that organisations – and their investors - re-evaluate how they plan, and commission clinical research as well as understand the benefits of using new trial designs across systems and territories.

Read the article in full, visit - www.healthinvestor.co.uk/feature/game-changer/

Latest news

Richmond Pharmacology Announces Promotion of Dr Priscilla Ochuba to Associate Medical Director

August 1, 2025
Richmond Pharmacology is pleased to announce the promotion of Dr Priscilla Ochuba to Associate Medical Director, effective 1st August 2025.
Read more

Red4Research Blog – Alan’s Story

June 24, 2025
#Red4Research is a global initiative that recognises the essential role of clinical research in improving treatment, outcomes, and the future of medicine.
Read more

Events

JSCPT 2025

5th –6th December 2025
Richmond Pharmacology will attend JSCPT 2025 in Tokyo, represented by their leadership team. Topics include early-phase studies, bridging studies between Europe and Asia, gene and RNA-based therapy development, and cross-border collaboration.
View event